aro-hsd
Nucleic acidexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2020 (NCT04202354)
Timeline
Indications
Mechanism of action
HSD17B1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06613698 | Phase 2 | Sep 27, 2024 | GlaxoSmithKline |
| NCT06104319 | Phase 2 | Jan 9, 2024 | GlaxoSmithKline |
| NCT05583344 | Phase 2 | Jan 4, 2023 | GlaxoSmithKline |
| NCT04202354 | Phase 1 | Feb 1, 2020 | Arrowhead Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 1 | 2023 |
| Arrowhead Pharmaceuticals | For profit | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1